U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07533266) titled 'Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer' on April 08.
Brief Summary: The study aims to demonstrate the preventive effect of Fexuprazan 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of Fexuprazan 20 mg.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
NSAID (Non-Steroidal Anti-Inflammatory Drug)
Intervention:
DRUG: Fexuprazan 20mg
Fexuprazan 20mg, tablet, orally, once daily for up to 24 weeks
DRUG: Lansoprazole 15 mg placebo
Lansoprazole 15mg placebo matching ca...